Denali Therapeutics Inc., was incorporated in Delaware in October 2013. Their goal is to discover and develop therapeutic drugs that can defeat neurodegenerative diseases. Neurodegeneration represents one of the most important unmet medical needs of their era, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or ALS, and other neurodegenerative diseases. The burden of these diseases on patients and society is enormous. They believe now is the right time for them to use their strong and ambitious efforts to defeat neurodegeneration. They believe that they can achieve success in a field with little success because of their rich experience of success, dedicated team of scientists and drug developers, their focused scientific strategy, and their proprietary blood-brain barrier (BBB) platform delivery technology. They are developing a broad portfolio of targeted therapy candidates for neurodegenerative diseases and recently started their first clinical trial. They started operations in May 2015.
